Clinical Report: Assessment of Tildrakizumab's Effectiveness and Safety

Overview

This report evaluates the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis and diabetes mellitus, based on a pooled analysis from the reSURFACE 1 and reSURFACE 2 trials. The findings indicate that tildrakizumab maintains efficacy in this population, although there is a noted increase in treatment-emergent adverse events among patients with diabetes.

Background

Psoriasis is a chronic inflammatory disease that is associated with an increased risk of diabetes mellitus and obesity. The severity of psoriasis correlates with the risk of developing diabetes, which can complicate treatment outcomes. Understanding the efficacy and safety of psoriasis treatments like tildrakizumab in patients with comorbid diabetes is crucial for optimizing patient care.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

• Tildrakizumab demonstrated maintained efficacy in achieving PASI 75 and PGA 0/1 responses at week 12 in patients with diabetes mellitus.
• Patients with diabetes mellitus had a numerically higher frequency of treatment-emergent adverse events compared to those without diabetes.
• Serious adverse events were particularly higher in patients with diabetes and comorbid obesity.
• The results align with the overall findings from the reSURFACE 1 and reSURFACE 2 trials.
• Patients with uncontrolled diabetes were excluded from the study, ensuring a focus on those with manageable diabetes.

Clinical Implications

Clinicians should be aware that while tildrakizumab is effective for treating psoriasis in patients with diabetes, there may be an increased risk of adverse events, particularly in those with obesity. Monitoring and managing comorbid conditions is essential for optimizing treatment outcomes.

Conclusion

The analysis supports the use of tildrakizumab in patients with moderate-to-severe plaque psoriasis and diabetes, highlighting its efficacy while also emphasizing the need for careful monitoring of adverse events in this population.

References

1. Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2 - PMC, 2023
2. Sustained Management of Psoriatic Arthritis with Guselkumab Across Various Domains and Patient Profiles: Insights from a Phase 3 Study Post Hoc Analysis, Clinical Rheumatology, 2024
3. Assessment of ixekizumab's safety and effectiveness in active psoriatic arthritis patients, with and without the use of conventional disease-modifying antirheumatic drugs: Findings from the SPIRIT-P1 and SPIRIT-P2 studies over three years, Clinical Rheumatology, 2022
4. Evaluating the Tolerability of Ixekizumab in Chinese Adults Suffering from Moderate-to-Severe Plaque Psoriasis: Insights from a 12-Week Prospective, Single-Arm, Multicenter Observational Study, Drug Safety, 2024
5. Clinical Rheumatology — Effectiveness of Certolizumab Pegol With and Without Disease-Modifying Anti-Rheumatic Drugs Over Four Years in Patients with Psoriatic Arthritis: Findings from the RAPID-PsA Randomized Controlled Trial
6. 2025 EuroGuiDerm Guidelines on Diabetes and Psoriasis
7. Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2 - PMC